Clinical value of measuring serum osteoprotegerin in patients with prostate cancer.
10.3760/cma.j.issn.1008-6315.2010.12.004
- VernacularTitle:前列腺癌患者血清骨保护素测定的临床价值
- Author:
Xuezhi ZHAO
;
Gang LI
;
Zhenjie WANG
;
Jinxian PU
;
Chunyin YAN
;
Qing SUN
;
Qifeng CHEN
;
Rong YIN
- Publication Type:Journal Article
- Keywords:
Serum osteoprotegerin;
Prostate cancer;
Bone metastases;
Gleason score
- From:
Clinical Medicine of China
2010;26(12):1242-1243
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the clinical value of measuring the concentration of serum osteoprotegerin (OPG) in detecting the bone metastases in patients with prostate cancer. Methods The concentration of serum OPG in 40 patients was determined by ELISA. The data of ECT bone scan and Gleason score was collected simultaneously. The correlations between serum OPG and bone metastases, Gleason score were tested. Results The concentration of serum OPG in patients with bone metastases by ECT scan was( 16 237. 19 ±5144. 26) ng/L,which was significantly higher than the concentration in patients without bone metastases , which was (12 123.32 ±4136. 50)ng/L. There was no significant correlation between serum OPG and Gleason score. Conclusions The serum OPG has an important clinical value in prediction of prostate cancer with bone metastases. There is no significant correlation between serum OPG and the Gleason score.
